Molecular Nuclear Diagnostics enables physicians to accurately diagnose complex diseases, including cancer, cardiovascular and neurological disorders in their early stages, and improve follow-up. Patients are injected with a radiopharmaceutical tracer and imaged with PET (Positron Emission Tomography) or SPECT (Single Photon Emission Computed Tomography) cameras.
PET is a state-of-the-art technique in Molecular Nuclear Diagnostics. PET scans with FDG (FluoroDeoxyGlucose), have been a revolutionary breakthrough in cancer treatment. They allow physicians to more accurately determine the precise stage of many tumors, localize unknown metastases and monitor therapeutic efficacy or the reoccurrence of the disease. PET radiopharmaceuticals are complex and challenging to produce as they are generally short-lived; fluorine-based molecules such as FDG, must, once produced, be transported and administered to patients in less than 10 hours. Today PET is also used in other therapy areas such as neurology, cardiology and infectious & inflammatory diseases.
SPECT has been used for over 50 years and today accounts for the majority of the molecular nuclear diagnostics market. A radioisotope, usually technetium-99m, is injected into the patient and through the blood stream reaches the lesion where it emits single gamma rays that are detected by the SPECT camera. SPECT is used to diagnose a wide range of conditions within oncology, cardiology, neurology and in the diagnosis of infectious diseases. In 2009, AAA acquired GiPharma, an Italian pharmaceutical contract manufacturer for injectable and freeze-dried products with over 30 years’ experience in SPECT manufacturing.